IntoCell인투셀
287840 · KOSDAQ · ₩287840 · 인투셀
₩15,980▼ ₩120 (0.75%)End-of-day · Oct 27, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | |
|---|---|---|---|
| Gross margin | — | — | — |
| Operating margin | −279.0% | −448.0% | −337.0% |
| Net margin | −275.9% | −461.2% | −341.2% |
Growth (year on year)
| TTM | 2025 | 2024 | |
|---|---|---|---|
| Revenue growth | +38.8% | −20.9% | — |
| Operating income growth | +13.5% | −5.2% | — |
| Net income growth | +17.0% | −7.0% | — |
Returns
| TTM | 2025 | 2024 | |
|---|---|---|---|
| Return on equity | −39.7% | −65.7% | −131.8% |
| Return on assets | −22.6% | −32.6% | −41.8% |
Leverage and liquidity
| TTM | 2025 | 2024 | |
|---|---|---|---|
| Liabilities to equity | 85.7% | 66.7% | 215.2% |
| Net debt to equity | −3.1% | −8.0% | 40.4% |
| Current ratio | 184.6% | 970.9% | 99.9% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: IntoCell / 인투셀 / 287840 / KRX:287840
Source: KRX statistical information